Replies to post #214409 on Biotech Values

[DewDiligence]

NVO—FDA approves Ozempic—a weekly version of Victoza—for T2D:

https://globenewswire.com/news-release/2017/12/05/1229378/0/en/Ozempic-semaglutide-approved-in-the-US.html